Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

18.2%

10 terminated/withdrawn out of 55 trials

Success Rate

54.5%

-32.0% vs industry average

Late-Stage Pipeline

2%

1 trials in Phase 3/4

Results Transparency

125%

15 of 12 completed trials have results

Key Signals

15 recruiting15 with results5 withdrawn

Enrollment Performance

Analytics

Phase 2
28(50.9%)
Phase 1
19(34.5%)
N/A
5(9.1%)
Early Phase 1
2(3.6%)
Phase 3
1(1.8%)
55Total
Phase 2(28)
Phase 1(19)
N/A(5)
Early Phase 1(2)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (55)

Showing 20 of 55 trials
NCT06263153Phase 2Recruiting

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

Role: collaborator

NCT02344355Phase 2Active Not Recruiting

A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme

Role: collaborator

NCT06200155Phase 2Recruiting

Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

Role: collaborator

NCT03657576Phase 1Completed

Trial of C134 in Patients With Recurrent GBM

Role: collaborator

NCT07222215Phase 2Recruiting

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

Role: collaborator

NCT07021989Phase 2Recruiting

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

Role: collaborator

NCT07735624Phase 2Recruiting

RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer

Role: collaborator

NCT05030441Phase 2Active Not Recruiting

Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1

Role: collaborator

NCT05721248Phase 2Active Not Recruiting

STOP-HER2: Stopping Trastuzumab in HER2+ MBC

Role: collaborator

NCT05318469Phase 1Recruiting

Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

Role: collaborator

NCT05458284Phase 2Active Not Recruiting

The Effect of Acupuncture on Nerve Pain Caused by Taxane (Chemotherapy) Treatment

Role: collaborator

NCT01591356Phase 1Active Not Recruiting

EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors

Role: collaborator

NCT03006848Phase 2Completed

A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma

Role: collaborator

NCT03093909Phase 1Recruiting

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

Role: collaborator

NCT04416568Phase 2Active Not Recruiting

Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

Role: collaborator

NCT02553460Phase 1Active Not Recruiting

Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I

Role: collaborator

NCT07217990Phase 1Not Yet Recruiting

Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer

Role: collaborator

NCT05029999Phase 1Recruiting

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

Role: collaborator

NCT04483206Phase 1Recruiting

Personalized Autologous Transplant for Multiple Myeloma

Role: collaborator

NCT03808558Phase 2Active Not Recruiting

Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas

Role: collaborator